See more : Yourgene Health Plc (VILGF) Income Statement Analysis – Financial Results
Complete financial analysis of CareRx Corporation (CHHHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CareRx Corporation, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- VERBUND AG (OEZVY) Income Statement Analysis – Financial Results
- G R Infraprojects Limited (GRINFRA.NS) Income Statement Analysis – Financial Results
- Barloworld Limited (BAW.JO) Income Statement Analysis – Financial Results
- Unitronix Corporation (UTRX) Income Statement Analysis – Financial Results
- Arafura Rare Earths Limited (ARU.AX) Income Statement Analysis – Financial Results
CareRx Corporation (CHHHF)
About CareRx Corporation
CareRx Corporation, together with its subsidiaries, provides specialty pharmacy services to seniors in Canada. The company operates a network of pharmacy fulfilment centers that provide chronic medication and other specialty clinical pharmacy services. It serves approximately 50,000 residents in approximately 900 seniors and other communities, including long-term care homes, retirement homes, assisted living facilities, and group homes. The company was formerly known as Centric Health Corporation and changed its name to CareRx Corporation in June 2020. CareRx Corporation was incorporated in 2001 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 370.75M | 381.73M | 262.63M | 162.20M | 124.63M | 123.74M | 168.97M | 167.36M | 162.42M | 308.07M | 455.86M | 436.65M | 200.99M | 62.48M | 36.62M | 15.80M | 14.25M | 12.32M | 9.42M | 7.14M | 6.83M | 2.88M |
| Cost of Revenue | 266.05M | 271.79M | 187.35M | 115.14M | 85.24M | 88.65M | 107.68M | 104.48M | 104.46M | 185.18M | 238.46M | 221.06M | 145.18M | 46.10M | 26.19M | 9.98M | 9.66M | 10.55M | 8.63M | 1.62M | 1.76M | 794.07K |
| Gross Profit | 104.70M | 109.93M | 75.28M | 47.05M | 39.38M | 35.10M | 61.29M | 62.88M | 57.96M | 122.90M | 217.40M | 215.60M | 55.82M | 16.38M | 10.44M | 5.82M | 4.59M | 1.77M | 790.82K | 5.52M | 5.07M | 2.08M |
| Gross Profit Ratio | 28.24% | 28.80% | 28.66% | 29.01% | 31.60% | 28.36% | 36.27% | 37.57% | 35.69% | 39.89% | 47.69% | 49.37% | 27.77% | 26.22% | 28.49% | 36.82% | 32.18% | 14.35% | 8.39% | 77.29% | 74.22% | 72.42% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.66M | 34.43M | 25.13M | 20.68M | 19.07M | 20.45M | 24.78M | 24.12M | 26.77M | 54.76M | 129.22M | 116.90M | 14.45M | 8.66M | 7.09M | 3.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.66M | 34.43M | 25.13M | 20.68M | 19.07M | 20.45M | 24.78M | 24.12M | 26.77M | 54.76M | 129.22M | 116.90M | 14.45M | 8.66M | 7.09M | 3.96M | 3.23M | 1.22M | 1.04M | 4.79M | 3.79M | 59.82K |
| Other Expenses | 69.37M | 67.87M | 45.34M | 27.79M | 22.81M | -922.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 50.50M | -349.00K | -71.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 100.03M | 102.30M | 70.47M | 48.46M | 41.88M | 41.66M | 54.61M | 59.46M | 64.09M | 122.72M | 225.29M | 213.01M | 52.17M | 9.16M | 7.47M | 4.14M | 3.51M | 1.49M | 1.35M | 5.04M | 3.98M | 59.82K |
| Cost & Expenses | 366.08M | 374.09M | 257.82M | 163.61M | 127.12M | 130.30M | 162.29M | 163.94M | 168.55M | 307.90M | 463.76M | 434.07M | 197.34M | 55.26M | 33.65M | 14.11M | 13.18M | 12.04M | 9.98M | 6.66M | 5.74M | 59.82K |
| Interest Income | 1.26M | 278.00K | 58.00K | 58.00K | 90.00K | 0.00 | 2.00K | 278.00K | 189.00K | 777.00K | 11.00K | 30.00K | 93.00K | 42.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.11K |
| Interest Expense | 14.27M | 15.22M | 14.49M | 1.22M | 23.67M | 7.39M | 7.07M | 15.11M | 27.90M | 27.82M | 24.96M | 15.72M | 12.25M | 664.00K | 433.00K | 0.00 | 0.00 | 0.00 | 0.00 | 45.50K | 111.03K | 366.00 |
| Depreciation & Amortization | 19.98M | 20.07M | 15.39M | 11.46M | 9.33M | 9.65M | 9.52M | 11.64M | 27.76M | 29.71M | 34.58M | 35.44M | 14.57M | 496.00K | 371.00K | 173.70K | 284.38K | 272.17K | 310.28K | 246.47K | 188.39K | 222.26K |
| EBITDA | 24.65M | -610.00K | 20.11M | 8.52M | -6.59M | 3.09M | 12.54M | 11.97M | 13.55M | 24.79M | 24.09M | 29.40M | 10.04M | 7.42M | 3.34M | 1.85M | 1.36M | 552.30K | -250.77K | 725.77K | 1.28M | 345.01K |
| EBITDA Ratio | 6.65% | 7.33% | 7.66% | 5.25% | 5.25% | 2.49% | 8.16% | 7.15% | 8.64% | 8.05% | 3.39% | 6.73% | 34.19% | 11.87% | 9.12% | 11.74% | 9.54% | 4.48% | -2.66% | 10.16% | 18.74% | -2.08% |
| Operating Income | 4.67M | 7.91M | 4.71M | -2.94M | -2.79M | -10.95M | 996.00K | -3.37M | -11.41M | -5.21M | -13.29M | -9.27M | 54.15M | 7.23M | 2.97M | 1.68M | 1.07M | 280.13K | -561.05K | 479.30K | 1.09M | -59.82K |
| Operating Income Ratio | 1.26% | 2.07% | 1.79% | -1.81% | -2.23% | -8.85% | 0.59% | -2.02% | -7.02% | -1.69% | -2.92% | -2.12% | 26.94% | 11.57% | 8.11% | 10.64% | 7.54% | 2.27% | -5.96% | 6.71% | 15.98% | -2.08% |
| Total Other Income/Expenses | -14.27M | -13.95M | -20.43M | -5.98M | -36.80M | -28.58M | -3.32M | -30.58M | -31.03M | -34.04M | -18.75M | -10.08M | -6.36M | -3.04M | -433.00K | 0.00 | 0.00 | 0.00 | 0.00 | -45.50K | -111.03K | -33.35K |
| Income Before Tax | -9.60M | -35.90M | -23.74M | -18.30M | -39.58M | -37.71M | -2.00M | -27.15M | -43.04M | -39.25M | -91.54M | -7.93M | -10.90M | 6.26M | 2.54M | 1.68M | 1.07M | 280.13K | -561.05K | 433.81K | 981.17K | 89.40K |
| Income Before Tax Ratio | -2.59% | -9.40% | -9.04% | -11.28% | -31.76% | -30.48% | -1.19% | -16.22% | -26.50% | -12.74% | -20.08% | -1.82% | -5.42% | 10.01% | 6.93% | 10.64% | 7.54% | 2.27% | -5.96% | 6.07% | 14.36% | 3.11% |
| Income Tax Expense | -4.19M | -1.54M | -1.01M | -118.00K | 6.10M | -3.33M | -1.48M | -8.87M | -6.74M | -1.66M | -694.00K | -841.00K | -1.92M | 1.93M | 897.00K | 728.90K | 320.24K | 230.66K | -212.97K | 303.20K | 375.69K | 59.08K |
| Net Income | -5.41M | -34.35M | -22.73M | -18.18M | -45.68M | -31.09M | 2.28M | -19.68M | 46.08M | -57.45M | -91.09M | -7.26M | -8.98M | 4.33M | 1.64M | 952.00K | 754.69K | 49.47K | -348.09K | 130.61K | 488.74K | -59.08K |
| Net Income Ratio | -1.46% | -9.00% | -8.65% | -11.21% | -36.65% | -25.13% | 1.35% | -11.76% | 28.37% | -18.65% | -19.98% | -1.66% | -4.47% | 6.93% | 4.48% | 6.03% | 5.30% | 0.40% | -3.69% | 1.83% | 7.15% | -2.05% |
| EPS | -0.09 | -0.72 | -0.65 | -0.90 | -4.16 | -3.05 | 0.20 | -2.39 | 5.80 | -7.91 | -14.12 | -1.27 | -2.23 | 1.41 | 0.64 | 0.52 | 0.60 | 0.04 | -0.28 | 0.20 | 1.00 | -0.37 |
| EPS Diluted | -0.09 | -0.72 | -0.65 | -0.90 | -4.16 | -3.05 | 0.20 | -2.39 | 5.80 | -7.91 | -9.85 | -0.94 | -1.75 | 1.19 | 0.50 | 0.52 | 0.60 | 0.04 | -0.26 | 0.20 | 1.00 | -0.37 |
| Weighted Avg Shares Out | 57.35M | 47.60M | 34.86M | 20.27M | 10.98M | 10.18M | 9.74M | 8.22M | 7.97M | 7.26M | 6.45M | 5.71M | 4.03M | 3.06M | 2.55M | 1.83M | 1.41M | 1.26M | 1.26M | 1.02M | 858.79K | 158.33K |
| Weighted Avg Shares Out (Dil) | 57.35M | 47.60M | 34.86M | 20.27M | 10.98M | 10.18M | 9.74M | 8.22M | 7.97M | 7.26M | 9.25M | 7.70M | 5.12M | 3.63M | 3.30M | 1.85M | 1.44M | 1.27M | 1.32M | 1.09M | 858.79K | 158.33K |
CareRx Corporation posts 4Q 2022 results reflecting a year of "exceptional progress"
CareRx Corporation (TSX:CRRX) has reported its financial results for the fourth quarter ended December 31, 2022, during which a key success was winning a multi-year contract to provide pharmacy services to residents in multiple seniors living facilities in Atlantic Canada....
CareRx earns repeat ‘Buy' rating from Canaccord analysts with reduced price target following equity financing
Canaccord Genuity (TSX:CF, LSE:CF) analysts have reiterated their ‘Buy' rating for CareRx Corporation (TSX:CRRX) but reduced their price target after the Canadian healthcare company raised equity financing. CareRx announced on January 18 it completed a bought deal offering and closed the...
CareRx closes $12.1 million financing to boost treasury
CareRx Corporation (TSX:CRRX) announced that it has completed its bought deal public offering and closed the first tranche of the concurrent private placement for aggregate gross proceeds of around $12.1 million. The Canadian healthcare company issued an aggregate of 2,998,000...
CareRx's 3Q results "solid" in spite of inflationary headwinds and healthcare spending, analysts say
Long-term care pharmacy service provider CareRx Corporation (TSX:CRRX) has managed to withstand the macro challenges facing its business, according to analysts at Leede Jones Gable. The company posted a significant jump in its third-quarter revenue, which was driven by acquisitions...
Source: https://incomestatements.info
Category: Stock Reports